Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors

NCT01460134 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT01460134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01460134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2011
Completion date
October 16, 2017
Enrollment
90 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

any t-cell malignancy, burkett's lymphoma, cd27 expressing b-cell malignancies for example hodgkin's lymphoma, chronic lymphocytic leukemia, colorectal adenocarcinoma, non-small cell lung cancer), hormone-refractory prostate adenocarcinoma, ovarian cancer, mantle cell lymphoma, marginal zone b cell lymphoma), primary lymphoma of the central nervous system, solid tumors (metastatic melanoma, renal (clear) cell carcinoma